fluorouracil accord
pharmacy retailing (nz) ltd t/a healthcare logistics - fluorouracil 50 mg/ml; - solution for injection - 250 mg/5ml - active: fluorouracil 50 mg/ml excipient: hydrochloric acid sodium hydroxide water for injection - alone or in combination, for the palliative treatment of malignant tumours, particularly of the breast, colon or rectum; and in the treatment of gastric, primary hepatic, pancreatic, uterine (cervical particularly), ovarian and bladder carcinomas. fluorouracil should only be used when other proven measures have failed or are considered impractical.
fluorouracil accord
pharmacy retailing (nz) ltd t/a healthcare logistics - fluorouracil 50 mg/ml; - solution for injection - 2500 mg/50ml - active: fluorouracil 50 mg/ml excipient: hydrochloric acid sodium hydroxide water for injection - alone or in combination, for the palliative treatment of malignant tumours, particularly of the breast, colon or rectum; and in the treatment of gastric, primary hepatic, pancreatic, uterine (cervical particularly), ovarian and bladder carcinomas. fluorouracil should only be used when other proven measures have failed or are considered impractical.
fluorouracil accord
pharmacy retailing (nz) ltd t/a healthcare logistics - fluorouracil 50 mg/ml; - solution for injection - 500 mg/10ml - active: fluorouracil 50 mg/ml excipient: hydrochloric acid sodium hydroxide water for injection - alone or in combination, for the palliative treatment of malignant tumours, particularly of the breast, colon or rectum; and in the treatment of gastric, primary hepatic, pancreatic, uterine (cervical particularly), ovarian and bladder carcinomas. fluorouracil should only be used when other proven measures have failed or are considered impractical.
fluorouracil accord
pharmacy retailing (nz) ltd t/a healthcare logistics - fluorouracil 50 mg/ml; - solution for injection - 5000 mg/100ml - active: fluorouracil 50 mg/ml excipient: hydrochloric acid sodium hydroxide water for injection - alone or in combination, for the palliative treatment of malignant tumours, particularly of the breast, colon or rectum; and in the treatment of gastric, primary hepatic, pancreatic, uterine (cervical particularly), ovarian and bladder carcinomas. fluorouracil should only be used when other proven measures have failed or are considered impractical.
fluorouracil 25 mg/ml solution for inj/inf
hospira uk limited - fluorouracil sodium - solution for inj/inf - 25 mg/ml - pyrimidine analogues
fluorouracil injection solution
sandoz canada incorporated - fluorouracil - solution - 50mg - fluorouracil 50mg - antineoplastic agents
fluoroplex cream 1%
allergan herbert skin care division of allergan inc. - fluorouracil - cream - 1% - fluorouracil 1% - misc. skin and mucous membrane agents
fluorouracil injection solution
pfizer laboratories div pfizer inc. - fluorouracil (unii: u3p01618rt) (fluorouracil - unii:u3p01618rt) - fluorouracil 50 mg in 1 ml
fluorouracil ebewe fluorouracil 2500 mg/50 ml solution for injection vial
sandoz pty ltd - fluorouracil, quantity: 2500 mg - injection, solution - excipient ingredients: water for injections; sodium hydroxide - alone or in combination, for the palliative treatment of malignant tumours, particularly of the breast, colon or rectum; and in the treatment of gastric, primary hepatic, pancreatic, uterine (cervical particularly), ovarian and bladder carcinomas. fluorouracil should only be used when other proven measures have failed or are considered impractical.
fluorouracil- fluorouracil injection, solution
sandoz inc - fluorouracil (unii: u3p01618rt) (fluorouracil - unii:u3p01618rt) - fluorouracil injection, usp is effective in the palliative management of carcinoma of the colon, rectum, breast, stomach and pancreas. fluorouracil therapy is contraindicated for patients in a poor nutritional state, those with depressed bone marrow function, those with potentially serious infections or those with a known hypersensitivity to fluorouracil.